{"entity":{"id":"nct06277219","kind":"trial","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","aka":[],"tldr":"A phase 1/2 trial of LAT010 in advanced solid tumours, run by Latticon Antibody Therapeutics, Inc, now recruiting.","summary":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) is a phase 1/2 interventional study registered as NCT06277219 by Latticon Antibody Therapeutics, Inc, with 150 participants planned, started 2024-06-05 and due to reach its primary completion in 2026-12. Interventions recorded: LAT010 and LAT010 + ICI.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06277219","url":"https://clinicaltrials.gov/study/NCT06277219"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06277219","phase":"1/2","setting":"A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","sponsor":"Latticon Antibody Therapeutics, Inc","enrolled":150,"outcomes":[]},"route":"/trials/nct06277219/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}